Physician profile
Jose Rivera
NPI 1184611626
$7,165.58
in general payments reported to CMS, 2019-2025
40 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $555 · 2021: $1,272 · 2022: $1,236 · 2023: $1,191 · 2024: $950 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,699.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,478.40 | 2019-2025 | |
| Amgen INC. | $676.13 | 2019-2025 | Repatha, Uplizna, Krystexxa |
| Novo Nordisk INC | $523.18 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $389.42 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $375.73 | 2022-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $317.03 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $292.76 | 2020-2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $284.44 | 2022-2025 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $267.91 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $263.82 | 2019-2024 | |
| Jenavalve Technology, INC. | $256.50 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $228.99 | 2019-2023 | Lifevest |
| Itamar Medical INC | $216.51 | 2022-2025 | Watchpatone |
| Heartflow, INC. | $180.00 | 2021-2024 | |
| Astellas Pharma US INC | $154.01 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $135.48 | 2019-2025 | Evkeeza, Praluent |
| Bayer Healthcare Pharmaceuticals INC. | $105.33 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $103.89 | 2024 | Arcalyst |
| Shionogi INC | $90.95 | 2023-2024 | Fetroja |
| Astrazeneca Pharmaceuticals Lp | $75.74 | 2020-2022 | |
| Medtronic Vascular, INC. | $71.44 | 2020 | |
| Bridgebio Pharma, INC. | $67.88 | 2025 | Attruby |
| Siemens Medical Solutions USA, INC. | $63.60 | 2022-2025 | Somatom Pro.Pulse |
| Cumberland Pharmaceuticals, INC. | $61.65 | 2024 | Vibativ |
| Impulse Dynamics (USA) INC. | $61.62 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $53.09 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.64 | 2020-2024 | Jardiance |
| Boston Scientific Corporation | $43.69 | 2019-2021 | |
| Medtronic, INC. | $38.07 | 2025 | Linq II |
| Cardiva Medical, INC. | $33.75 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Arbor Pharmaceuticals, INC. | $25.75 | 2019-2020 | |
| Kerecis Limited | $25.47 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Tactile Systems Technology INC | $25.00 | 2021 | |
| Vifor Pharma, INC. | $24.90 | 2019 | |
| Lantheus Medical Imaging, INC. | $24.32 | 2019 | |
| Inspire Medical Systems, INC. | $20.21 | 2023 | Inspire |
| Baxter Healthcare | $19.65 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, Ltd. | $16.58 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $13.48 | 2019 | |
| Lundbeck LLC | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.